Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H25NO3.ClH |
Molecular Weight | 315.836 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C
InChI
InChIKey=IPWGSXZCDPTDEH-UHFFFAOYSA-N
InChI=1S/C16H25NO3.ClH/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6;/h9-11H,7-8H2,1-6H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H25NO3 |
Molecular Weight | 279.3746 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/9711459Curator's Comment: description was created based on several sources, including
https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false
http://www.ncbi.nlm.nih.gov/pubmed/1475074
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Curator's Comment: description was created based on several sources, including
https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false
http://www.ncbi.nlm.nih.gov/pubmed/1475074
Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction, also was studied, that this drug may be useful to treat ocular disorders such as diabetic retinopathy. It is an alpha1-adrenergic antagonist. Was developed for self-injection therapy in France and marketed in several European countries as Icavex. In the spring 2005 the manufacturer of Icavex decided to withdraw this drug from Europe market, presumable due to its low market shares.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10699651 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Ergotamine-induced peripheral ischaemia reversed by oral thymoxamine hydrochloride. | 1986 Jan |
|
Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. | 2000 Mar 15 |
|
Assessment of the intrinsic urethral sphincter component function in postprostatectomy urinary incontinence. | 2002 |
|
Noradrenergic control of arginine vasopressin release from the ewe hypothalamus in vitro: sensitivity to oestradiol. | 2008 Apr |
|
Oral vasodilators for primary Raynaud's phenomenon. | 2008 Apr 16 |
|
Raynaud's phenomenon (primary). | 2008 Dec 16 |
|
Raynaud's phenomenon (secondary). | 2008 Sep 26 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Intracavernous injection of moxisylyte at 10, 20 or 30 mg can induce an erection adequate for intercourse in most of the patients
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2522580
Moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue was investigated and compared with other alpha-adrenergic antagonists. Moxisylyte produced a concentration-dependent relaxation of a norepinephrine-induced (1 x 10(-5) M) contraction of the corpus cavernosum tissue. Pretreatment with 1 x 10(-6) M doses of moxisylyte reduced competitively the norepinephrine-induced contraction
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:09:01 GMT 2023
by
admin
on
Fri Dec 15 15:09:01 GMT 2023
|
Record UNII |
WK2KZM9V6X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
19887
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m7648
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
964-52-3
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
13758
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
SUB03343MIG
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
C87585
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
DTXSID9046946
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
170448
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL159226
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
WK2KZM9V6X
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
213-519-4
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | |||
|
235778
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000088303
Created by
admin on Fri Dec 15 15:09:01 GMT 2023 , Edited by admin on Fri Dec 15 15:09:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |